Disposals of own shares | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Disposals of own shares

Brussels (Belgium), 3 January 2022 – 20:00 (CET) – regulated information

Disposal of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

In addition to these exercises, on 30 December 2021, in accordance with the vesting rules under its 2017 and 2018 LTI plans, UCB SA/NV has delivered for free a total of 5 021 UCB shares OTC to 2 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 30 December 2021 was € 101,05.

This press release is available on UCB SA/NV’s website via the following link.

Investor Relations
Antje Witte          
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Corporate Communications
Laurent Schots 
Media Relations, UCB  
T+32.2.559.92.64  Laurent.schots@ucb.com 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news


Asset Download

Chart 1 January 3 2022.png

Stay up-to-date on the latest news and information from UCB